Hamilton contract-development and manufacturing organization focused on cell and gene therapies, with an automation-oriented manufacturing platform and a corporate relationship to CCRM.
Operating context
OmniaBio’s Hamilton manufacturing base has a more concrete regulatory milestone than its Intelligent Factory development narrative alone suggests: the company reported receiving a Health Canada Drug Establishment License in December 2025. That facility authorization should be distinguished from approval of any individual therapy and from the automation systems still under development. Its June 2026 Avectas agreement remains an evaluation of a manufacturing platform. A separate July 2026 development expands the starting-material ecosystem: STEMCELL and CCRM agreed to supply matched research-use-only and GMP iPSC lines originating from LineaBio, which CCRM and OmniaBio founded together. Linea 1’s drug master file provides reference documentation for developers; it is not approval of the treatments they may develop. Together these details distinguish manufacturing services, platform evaluation and standardized cell-line access.
Canadian footprint
OmniaBio publishes an operating presence in Hamilton, Ontario, Canada, and its current public record anchors Intelligent Factory cell-and-gene-therapy manufacturing to that Canadian organization.
Hamilton, Ontario is the published city-level context for OmniaBio. It does not imply a street address or exact facility location.
The facility license, LineaBio starting materials and Avectas evaluation support different parts of a therapy-development pathway; no inspected source makes them interchangeable or confirms commercial deployment of the evaluated automation.
Interpretation of the public record. Not qualification, endorsement or evidence of buyer interest.
Advanced-therapy manufacturing and automation development
Read technical summary
OmniaBio offers cell and gene therapy manufacturing support while developing an Intelligent Factory approach to automation. The concept links predictive analytics, robotic processing, automated quality control and logistics to manufacturing workflows.
Evidence of maturity
The June 2026 Avectas agreement concerns evaluation within the developing Intelligent Factory. Existing manufacturing services should be distinguished from completion and validation of the full automation concept.
Commercial availability
Biotechnology sponsors can scope process development and manufacturing services; product-specific validation and regulatory requirements remain separate from automation partnerships.
Core features
Clinical and commercial cell-therapy manufacturing support
Proposed predictive analytics, robotics and automated quality control
Avectas platform evaluation with CCRM and OmniaBio
Recorded applications
Domestic advanced-therapy manufacturing capacity
Scale-up and technology transfer for cell therapies
OmniaBio currently presents Intelligent Factory cell-and-gene-therapy manufacturing as part of its public commercial offering.
Questions for a first conversation
01
Which licensed activities, cell-line documentation and automation components are included in a specific manufacturing engagement?
The facility license, LineaBio starting materials and Avectas evaluation support different parts of a therapy-development pathway; no inspected source makes them interchangeable or confirms commercial deployment of the evaluated automation.
Original sources 6 linked records
These records support the organization, its owned capabilities and their reviewed connections. A source count is not a count of independent confirmations.
CCRM and its subsidiary OmniaBio announced an agreement June 15, 2026 to evaluate Avectas automated cell-therapy manufacturing platform; evaluation would assess fit with scalable manufacturing workflows.
CCRM and its subsidiary OmniaBio announced an agreement June 15, 2026 to evaluate Avectas automated cell-therapy manufacturing platform; evaluation would assess fit with scalable manufacturing workflows.
CCRM and its subsidiary OmniaBio announced an agreement June 15, 2026 to evaluate Avectas automated cell-therapy manufacturing platform; evaluation would assess fit with scalable manufacturing workflows.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
CCRM and its subsidiary OmniaBio announced an agreement June 15, 2026 to evaluate Avectas automated cell-therapy manufacturing platform; evaluation would assess fit with scalable manufacturing workflows.
CCRM and its subsidiary OmniaBio announced an agreement June 15, 2026 to evaluate Avectas automated cell-therapy manufacturing platform; evaluation would assess fit with scalable manufacturing workflows.
Supports: Profile · operating context
CCRM and its subsidiary OmniaBio announced an agreement June 15, 2026 to evaluate Avectas automated cell-therapy manufacturing platform; evaluation would assess fit with scalable manufacturing workflows.
The June 2026 CCRM, OmniaBio and Avectas agreement is an evaluation of an automated manufacturing platform within the developing Intelligent Factory concept. OmniaBio offers clinical and commercial cell and gene therapy manufacturing support; product-specific process validation and regulatory requirements remain distinct from the automation evaluation.
Supports: Intelligent Factory cell-and-gene-therapy manufacturing · core features
The June 2026 CCRM, OmniaBio and Avectas agreement is an evaluation of an automated manufacturing platform within the developing Intelligent Factory concept. OmniaBio offers clinical and commercial cell and gene therapy manufacturing support; product-specific process validation and regulatory requirements remain distinct from the automation evaluation.
The June 2026 CCRM, OmniaBio and Avectas agreement is an evaluation of an automated manufacturing platform within the developing Intelligent Factory concept. OmniaBio offers clinical and commercial cell and gene therapy manufacturing support; product-specific process validation and regulatory requirements remain distinct from the automation evaluation.
Supports: Intelligent Factory cell-and-gene-therapy manufacturing · core features
The June 2026 CCRM, OmniaBio and Avectas agreement is an evaluation of an automated manufacturing platform within the developing Intelligent Factory concept. OmniaBio offers clinical and commercial cell and gene therapy manufacturing support; product-specific process validation and regulatory requirements remain distinct from the automation evaluation.
The June 2026 CCRM, OmniaBio and Avectas agreement is an evaluation of an automated manufacturing platform within the developing Intelligent Factory concept. OmniaBio offers clinical and commercial cell and gene therapy manufacturing support; product-specific process validation and regulatory requirements remain distinct from the automation evaluation.
OmniaBio publishes an operating presence in Hamilton, Ontario, Canada, and its current public record anchors Intelligent Factory cell-and-gene-therapy manufacturing to that Canadian organization.
STEMCELL and CCRM announced July 8, 2026 matched research-use-only and GMP iPSC distribution; LineaBio, founded by CCRM and OmniaBio, supplies GMP lines. Linea 1 is supported by an FDA drug master file, not a therapeutic marketing approval.
OmniaBio reported December 23, 2025 that Health Canada issued a Drug Establishment License for its Hamilton facility; the same announcement distinguishes existing CGT manufacturing from developing Intelligent Factory automation.
Public sources cited · Facts and assessments kept separate · Human review
Distinguish OmniaBio from parent CCRM and separate operating GMP services from planned automation; performance and capacity claims require program-level verification. The first conversation should therefore separate current offer, development evidence and accepted operational use.
Supports: Profile · organization categories
True North Map applies the commercial company category to OmniaBio from its documented mandate and source-bounded operating evidence.
Supports: Profile · organization categories
True North Map applies the dual use category to OmniaBio from its documented mandate and source-bounded operating evidence.
Supports: Profile · dual use posture
Intelligent Factory cell-and-gene-therapy manufacturing has documented civilian or industrial applications and a bounded potential relevance to Canadian defence, security or strategic-infrastructure needs.
True North Map derives a first-conversation question about Intelligent Factory cell-and-gene-therapy manufacturing configuration and accepted outcomes from the documented maturity boundary.
Supports: Profile · current activity as of
Innovation, Science and Economic Development Canada's dated record anchors this activity to 2026-06-15.
Supports: Profile · description
True North Map derives this executive description for OmniaBio from the official identity and technical records together with Innovation, Science and Economic Development Canada's corroborating evidence.
Supports: Profile · current activity
On June 15, 2026, CCRM, OmniaBio, and Avectas announced an evaluation agreement concerning cell-engineering and manufacturing technology.
Innovation, Science and Economic Development Canada's public evidence confirms a company-specific project, award, program or operating context, while configuration-specific acceptance and scale remain bounded by the reviewer warning.
OmniaBio publishes Ontario as its Canadian province or territory.
Supports: Profile · primary location.countrycode
OmniaBio publishes a Canadian operating presence, represented by country code CA.
Supports: Profile · name
OmniaBio is the public name used by the organization's official website.
Supports: Profile · entity kind
True North Map classifies OmniaBio as a company from its documented legal or institutional role.
Supports: Profile · primary location.longitude
True North Map uses the Hamilton city centroid longitude -79.8711 for a city-level map location.
Supports: Profile · legal name
OmniaBio Inc. is the legal name supported by the cited public record.
https://omniabio.com/contact/ is the public identity or contact route used for OmniaBio.
STEMCELL and CCRM announced July 8, 2026 matched research-use-only and GMP iPSC distribution; LineaBio, founded by CCRM and OmniaBio, supplies GMP lines. Linea 1 is supported by an FDA drug master file, not a therapeutic marketing approval.
STEMCELL and CCRM announced July 8, 2026 matched research-use-only and GMP iPSC distribution; LineaBio, founded by CCRM and OmniaBio, supplies GMP lines. Linea 1 is supported by an FDA drug master file, not a therapeutic marketing approval.
STEMCELL and CCRM announced July 8, 2026 matched research-use-only and GMP iPSC distribution; LineaBio, founded by CCRM and OmniaBio, supplies GMP lines. Linea 1 is supported by an FDA drug master file, not a therapeutic marketing approval.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
STEMCELL and CCRM announced July 8, 2026 matched research-use-only and GMP iPSC distribution; LineaBio, founded by CCRM and OmniaBio, supplies GMP lines. Linea 1 is supported by an FDA drug master file, not a therapeutic marketing approval.
Supports: Profile · operating context
STEMCELL and CCRM announced July 8, 2026 matched research-use-only and GMP iPSC distribution; LineaBio, founded by CCRM and OmniaBio, supplies GMP lines. Linea 1 is supported by an FDA drug master file, not a therapeutic marketing approval.
Supports: Profile · operating context
OmniaBio reported December 23, 2025 that Health Canada issued a Drug Establishment License for its Hamilton facility; the same announcement distinguishes existing CGT manufacturing from developing Intelligent Factory automation.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
OmniaBio reported December 23, 2025 that Health Canada issued a Drug Establishment License for its Hamilton facility; the same announcement distinguishes existing CGT manufacturing from developing Intelligent Factory automation.
OmniaBio reported December 23, 2025 that Health Canada issued a Drug Establishment License for its Hamilton facility; the same announcement distinguishes existing CGT manufacturing from developing Intelligent Factory automation.
OmniaBio reported December 23, 2025 that Health Canada issued a Drug Establishment License for its Hamilton facility; the same announcement distinguishes existing CGT manufacturing from developing Intelligent Factory automation.
OmniaBio reported December 23, 2025 that Health Canada issued a Drug Establishment License for its Hamilton facility; the same announcement distinguishes existing CGT manufacturing from developing Intelligent Factory automation.
OmniaBio currently presents Intelligent Factory cell-and-gene-therapy manufacturing as part of its public commercial offering.
Supports: Profile · operating context
OmniaBio operates from Hamilton, Ontario, with a public mandate centred on Intelligent Factory cell-and-gene-therapy manufacturing; public sources do not establish every customer, configuration or operational outcome.
Supports: Profile · profileData.portfolioScope
OmniaBio's documented portfolio in this dossier is bounded to Intelligent Factory cell-and-gene-therapy manufacturing and the source-backed functions listed below.
Supports: Intelligent Factory cell-and-gene-therapy manufacturing · name
OmniaBio's Intelligent Factory combines cell and gene therapy manufacturing services with proposed predictive analytics, robotics, automated quality control and logistics. The Intelligent Factory page describes an automation architecture and development direction; it does not establish regulatory approval for every tool or therapy.
OmniaBio's Intelligent Factory combines cell and gene therapy manufacturing services with proposed predictive analytics, robotics, automated quality control and logistics. The Intelligent Factory page describes an automation architecture and development direction; it does not establish regulatory approval for every tool or therapy.
Supports: Intelligent Factory cell-and-gene-therapy manufacturing · core features
Automation, robotics, and digital manufacturing controls
Supports: Intelligent Factory cell-and-gene-therapy manufacturing · capability type
OmniaBio's Intelligent Factory combines cell and gene therapy manufacturing services with proposed predictive analytics, robotics, automated quality control and logistics. The Intelligent Factory page describes an automation architecture and development direction; it does not establish regulatory approval for every tool or therapy.
OmniaBio's Intelligent Factory combines cell and gene therapy manufacturing services with proposed predictive analytics, robotics, automated quality control and logistics. The Intelligent Factory page describes an automation architecture and development direction; it does not establish regulatory approval for every tool or therapy.
True North Map maps Intelligent Factory cell-and-gene-therapy manufacturing to advanced manufacturing and integration from its documented technology functions.
OmniaBio's Intelligent Factory combines cell and gene therapy manufacturing services with proposed predictive analytics, robotics, automated quality control and logistics. The Intelligent Factory page describes an automation architecture and development direction; it does not establish regulatory approval for every tool or therapy.
Supports: Intelligent Factory cell-and-gene-therapy manufacturing · name
OmniaBio provides process development and GMP manufacturing services for cell and gene therapies while developing automation, robotics, analytics, and digital controls for manufacturing workflows. Planned intelligent-factory capabilities should be separated from currently validated GMP operations.
Supports: Intelligent Factory cell-and-gene-therapy manufacturing · core features
GMP cell-and-gene-therapy process and manufacturing services
OmniaBio's Intelligent Factory combines cell and gene therapy manufacturing services with proposed predictive analytics, robotics, automated quality control and logistics. The Intelligent Factory page describes an automation architecture and development direction; it does not establish regulatory approval for every tool or therapy.
OmniaBio's Intelligent Factory combines cell and gene therapy manufacturing services with proposed predictive analytics, robotics, automated quality control and logistics. The Intelligent Factory page describes an automation architecture and development direction; it does not establish regulatory approval for every tool or therapy.
OmniaBio's Intelligent Factory combines cell and gene therapy manufacturing services with proposed predictive analytics, robotics, automated quality control and logistics. The Intelligent Factory page describes an automation architecture and development direction; it does not establish regulatory approval for every tool or therapy.
Supports: Intelligent Factory cell-and-gene-therapy manufacturing · core features
OmniaBio's Intelligent Factory combines cell and gene therapy manufacturing services with proposed predictive analytics, robotics, automated quality control and logistics. The Intelligent Factory page describes an automation architecture and development direction; it does not establish regulatory approval for every tool or therapy.
Continue exploring
Follow the strongest connections
Continue through related organizations, reviewed mission and Defence need connections, programme pathways, and explicitly linked intelligence. Similarity results describe shared areas of work, not partnerships or endorsements.
Organizations
Profiles that provide the strongest reviewed or discovery-led continuation.
